Here’s what you should know.
1. Market analysts believe the deal puts pressure on Allergan to announce a significant deal to counteract the biosimilar announcement.
2. Mizuho Securities analyst Irina Koffler said, “We think Allergan [management] must now prepare for the prospect of a viable global biosimilar and make preemptive plans to diversify its business into other verticals rather than focus primarily on its international cosmetic build-out.”
3. Allergan is in the midst of acquiring Elastagen Pty, an injectable aesthetics product development company, but Allergan’s President and CEO Brent Saunders said 2018 “will be a relatively boring year for Allergan on the [acquisition] front.”
4. The Mylan announcement sent Allergan’s stock into a slump. The company’s stock lost 3.8 percent in value March 1. In 2018, Allergan’s stock has declined 9.3 percent to date.
More articles on supply chain:
Physicians Endoscopy supports Colon Cancer Awareness Month: 5 things to know
HSA PrimeCare opens complex with surgery center — 4 facts
Net revenue by specialty for ASCs in the Midwest — 10 statistics
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
